Luye Pharma Group today announced that its subsidiary Luye Pharma Switzerland AG has entered into agreements with Exeltis Pharma México, S.A. de C.V and Exeltis Pharmaceuticals Holding, S.L (Exeltis), ...
China’s National Medical Products Administration has approved Sino Biopharmaceutical Ltd.’s rivastigmine transdermal patch to treat mild to moderate Alzheimer’s disease. Developed by Sino Biopharm, ...
According to the World Health Organization (WHO), an estimated 50 million people are living with dementia globally. This number is projected to increase to 82 million by 2030 and over 150 million by ...
* MYLAN- U.S. LAUNCH OF RIVASTIGMINE TRANSDERMAL SYSTEM, 4.6 MG/24 HRS, 9.5 MG/24 HRS AND 13.3 MG/24 HRS, A GENERIC VERSION OF NOVARTIS' EXELON PATCH Source text for Eikon: Further company coverage: ...
NEW DELHI, Sept. 10, 2020 /PRNewswire/ -- "Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights: Download Report: https ...
ZURICH, Sept 24 (Reuters) - The European Union has approved Novartis's Exelon skin patch to treat Alzheimer's disease, the Swiss drugmaker said on Monday. "The European Commission has approved Exelon ...
"US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights: Download Report: https://www.kuickresearch.com/report-us-transdermal ...
The transdermal patches market is further segmented based on the patch type, adhesive type, application, distribution channel, end-user, and region. The Drug-In-Adhesives segment is expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback